Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Progenics Pharmaceuticals Inc. PGNX

Healthcare Biotechnology
"Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate... see more

Recent & Breaking News (NDAQ:PGNX)

Progenics Pharmaceuticals Presents Updated Data From Phase 1 Study of PSMA ADC

Troy Schwensen February 14, 2013

Biotech Companies Attractive Targets for Pharma Companies Looking to Replace Lost Revenues

Marketwired January 30, 2013

Progenics Acquires Molecular Insight Pharmaceuticals to Expand Oncology-Focused Pipeline

Troy Schwensen January 22, 2013

Which Biotech Companies Are Turning the Tables on Patent Cliffs?

PR Newswire January 14, 2013

Perfect Trade Setups, How to Play SGYP, CLSP, VTUS and PGNX

Marketwired January 3, 2013

The Real Story Behind PGNX, OSUR, NVGN and AGEN

Marketwired January 2, 2013

Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry's Success in 2012

Marketwired January 2, 2013

The Real Story Behind ALTE, EDAP, NEPT and PGNX

Marketwired December 20, 2012